Morgan Stanley Nymox Pharmaceutical Corp Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.33 - $0.5 $352 - $534	1,068 Added 1.09%	98,686 $33,000
Q4 2022 Feb 14, 2023	BUY	$0.28 - $0.74 $293 - $776	1,049 Added 1.09%	97,618 $31,000
Q3 2022 Nov 14, 2022	BUY	$0.22 - $0.61 $6,632 - $18,390	30,149 Added 45.39%	96,569 $40,000
Q2 2022 Oct 27, 2022	SELL	$0.38 - $1.41 $704 - $2,614	-1,854 Reduced 2.72%	66,420 $28,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $1.41 $704 - $2,614	-1,854 Reduced 2.72%	66,420 $28,000
Q1 2022 Oct 27, 2022	BUY	$1.21 - $2.0 $2,243 - $3,708	1,854 Added 2.79%	68,274 $86,000
Q1 2022 May 13, 2022	BUY	$1.21 - $2.0 $1,420 - $2,348	1,174 Added 1.75%	68,274 $86,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $2.1 $3,341 - $7,385	-3,517 Reduced 4.98%	67,100 $87,000
Q3 2021 Nov 15, 2021	BUY	$1.3 - $2.23 $91,802 - $157,475	70,617 New	70,617 $145,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.